MedTrace Logo

Antisecretory Factor Glioblastoma Phase 2

NCT05669820 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-01-09

No results posted yet for this study

Summary

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Conditions

Interventions

DIETARY_SUPPLEMENT

Salovum

Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.

DIETARY_SUPPLEMENT

Placebo egg yolk powder

Egg yolk powder derived from hen fed with normal feed.

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Peter Siesjö

    lead OTHER

Principal Investigators

  • Charlotte Edwardsson · Skane University Hospital

  • Erik Ehinger, MD · Skane University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2026-12-01
Completion
2027-12-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669820 on ClinicalTrials.gov